Fealy, N., Aitken, L. M., du Toit, E., Baldwin, I. & Lo, S. (2017). Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a randomised controlled trial (RCT). Paper presented at the The 41st Australian and New Zealand Scientific meeting on Intensive Care, October 2016, Perth, Australia.



City Research Online

Original citation: Fealy, N., Aitken, L. M., du Toit, E., Baldwin, I. & Lo, S. (2017). Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a randomised controlled trial (RCT). Paper presented at the The 41st Australian and New Zealand Scientific meeting on Intensive Care, October 2016, Perth, Australia.

Permanent City Research Online URL: http://openaccess.city.ac.uk/17388/

Copyright & reuse

City University London has developed City Research Online so that its users may access the research outputs of City University London's staff. Copyright © and Moral Rights for this paper are retained by the individual author(s) and/ or other copyright holders. All material in City Research Online is checked for eligibility for copyright before being made available in the live archive. URLs from City Research Online may be freely distributed and linked to from other web pages.

Versions of research

The version in City Research Online may differ from the final published version. Users are advised to check the Permanent City Research Online URL above for the status of the paper.

Enquiries

If you have any enquiries about any aspect of City Research Online, or if you wish to make contact with the author(s) of this paper, please email the team at <u>publications@city.ac.uk</u>.

BLOOD FLOW RATE AND CIRCUIT LIFE IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT): A RANDOMISED CONTROLLED TRIAL (RCT).

Nigel Fealy^{*} 1, 2, 3, Leanne Aitken^{2, 4, 5}, Eugene du Toit⁶, Ian Baldwin^{1, 3}, Serigne Lo⁷ ¹Department of Intensive Care, Austin Health, Melbourne, ²School of Nursing and Midwifery, Griffith University, Brisbane, ³School of Nursing and Midwifery, Deakin University, Melbourne, ⁴Princess Alexandra Hospital, Brisbane, Australia, ⁵City University London, London, United Kingdom, ⁶School of Medical Science, Griffith University, Gold Coast, ⁷Melanoma Institute of Australia, Sydney, Australia

There is minimal evidence to inform blood flow rate (BFR) during CRRT. We aimed to assess the effect of BFR on circuit life during CRRT.

A prospective RCT was conducted over one year in our tertiary ICU. Adult patients with acute kidney injury were randomised to either 150 or 250 mls/min. Circuit and patient data were collected until each circuit clotted or ceased electively. Duration data for clotted circuits are presented as median (Interquartile range) and compared using the log- rank test; p was set at <0.05. Circuit clotting data were analysed for repeated events using a hazards ratio (HR).

One hundred patients were randomised with 96 completing the study (150 mls/min-49; 250 mls/min-47) with 462 circuits; 245:150 mls/min and 217:250 mls/min. Median circuit life for 1St circuit (clotted) was similar for both groups (150 mls/min: 9.1 [5.5, 26] hrs vs. 10 [4.2, 17] hrs; p=0.37). Second and third circuits were also similar. 150 mls/min: 14 [8.5,21] hrs vs. 13.8 [8.5, 16.7] hrs; p=0.44. 150 mls/min:17 [10.5, 28.5] hrs vs.16 [12, 21.5] hrs; p=0.52 respectively . CRRT using 250 mls/min was not more likely to cause clotting compared to 150 mls/min (HR, 1.06 [0.63, 1.78]; p=0.36, variance of the random effect, 1.096 [0.23]). There were no differences in likelihood of clotting for: BMI, weight, vascular access type, length or site, mode of CRRT, INR or platelet count. CRRT with no use of anticoagulation was more likely to cause clotting compared to use of heparin or heparin/protamine (HR 1.61, [1.17, 2.21], p=0.002). Longer APTT was associated with a lower likelihood of circuit clotting (HR 0.98,[0.97, 0.99], p=0.002). Clotting was more probable in males (HR 1.64 [0.87, 3.08] p=0.02).

Blood flow rate did not effect clotting during CRRT. Males and use of anticoagulation and APTT were more likely to affect circuit survival.

Disclosure of Interest: None Declared